Novo Nordisk's shares have risen about 27% due to strong commercial growth of oral Wegovy, which holds 89% of new U.S. prescriptions compared to Eli Lilly's 11%. Over 80% of these prescriptions are from new GLP-1 patients, expanding the market rather than replacing injectables. The drug has received approvals in multiple regions including the U.S., UAE, UK, and EU, supporting a broad rollout that could boost revenues through 2027. Despite this momentum, consensus forecasts a Q2 revenue decline of 8.9% and EPS drop of 17.8% due to generic competition affecting injectable sales.
Novo Nordisk has received a Sell rating due to declining profits, weak revenue growth, and operational challenges despite its leading semaglutide product. The company's 2026 guidance predicts flat to negative sales and operating profit growth, contra...
Eli Lilly and Novo Nordisk both beat Q2 estimates and raised their full-year outlooks, but investors favored Lilly, boosting its shares while punishing Novo. Lilly leads the obesity drug market with a 60.9% U.S. share, driven by strong sales of Mounj...
